Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
LV Bioclin from Waterloo, company number BE0538733743, closed financial year 2025 with a result of € 178,313 after tax. For that financial year LV Bioclin recorded a gross margin of € 235,731 and equity of € 28,308. Compared with financial year 2024, the result moved from € 214,001 to € 178,313. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 28,308
▲ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 178,313
▼ 17% vs 2024
Profit after tax over the fiscal year.
€ 392,324
▲ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 175,000 paid out
98 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 628
▼ 58% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,234
▲ € 2,893 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,982
▼ 94% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 217,841 | € 202,931 | € 286,186 | € 235,731 | ▼ 18% |
| Profit after taxes | € 161,632 | € 151,170 | € 214,001 | € 178,313 | ▼ 17% |
| Equity | € 22,824 | € 23,995 | € 24,995 | € 28,308 | ▲ 13% |
| Total debts | € 200,892 | € 263,276 | € 391,800 | € 390,760 | |
| Cash | € 189,101 | € 231,763 | € 324,659 | € 392,324 | ▲ 21% |
| Retained profit | € 2,364 | € 3,535 | € 4,535 | € 7,848 | ▲ 73% |
| Dividend | € 161,600 | € 150,000 | € 213,000 | € 175,000 | ▼ 18% |
| Balance sheet total | € 223,717 | € 287,271 | € 416,796 | € 419,068 | ▲ 1% |
Key figures of LV Bioclin, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LV Bioclin?
What happened at LV Bioclin in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 178,313 (▼ 17% vs 2024). Source: NBB ↗
- New establishment in Schaarbeek. KBO
- Laurence Verdickt became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 161,632 profit in 2022 to € 178,313 profit in 2025.
Paid € 214,524 in corporate taxes since 2022.
Best year ever: 2024, with € 214,001 profit.
Paid out € 699,600 in dividends to the owners in total.
Management
Behind LV Bioclin is Laurence Verdickt. Laurence Verdickt is also behind MG Legal Consult.
Directors
According to the 2025 annual accounts
since 2013
Establishments
Establishment units
Physical locations of this company
Avenue d'Argenteuil 53
1410 Waterloo
Guillaume Kennisstraat 62
1030 Schaarbeek
Active since 14 October 2013
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0538.733.743
- VAT number
- BE 0538.733.743
- Registered office
- Avenue d'Argenteuil 53, 1410 Waterloo
- Names & denominations
- LV Bioclin
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 September 2013
- Peppol
- Not registered
- Contact
- [email protected] 0476344388